Peginterferon Alfa-2a Injection

Generic name: Pronounced as (peg in ter feer' on)
Brand names
  • Pegasys®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2016

Peginterferon alfa-2a may cause or worsen the following conditions, which may be serious or cause death: infections; mental illness including depression, mood and behavior problems, or thoughts of hurting or killing yourself; starting to use street drugs again if you used them in the past; ischemic disorders (conditions in which there is poor blood supply to an area of the body) such as angina (chest pain), heart attack, stroke, or colitis (inflammation of the bowels); and autoimmune disorders (conditions in which the immune system attacks one or more parts of the body) that may affect the blood, joints, kidneys, liver, lungs, muscles, skin, or thyroid gland. Tell your doctor if you have an infection; or if you have or have ever had an autoimmune disease; atherosclerosis (narrowing of the blood vessels from fatty deposits); cancer; chest pain; colitis; diabetes; heart attack; high blood pressure; high cholesterol; HIV (human immunodeficiency virus) or AIDS (acquired immunodeficiency syndrome); irregular heartbeat; mental illness including depression, anxiety, or thinking about or trying to kill yourself; liver disease other than hepatitis B or C; or heart, kidney, lung or thyroid disease. Also tell your doctor if you drink or have ever drunk large amounts of alcohol, or if you use or have ever used street drugs or have overused prescription medications. If you experience any of the following symptoms, call your doctor immediately: bloody diarrhea or bowel movements; stomach pain, tenderness or swelling; chest pain; irregular heartbeat; weakness; loss of coordination; numbness; changes in your mood or behavior; depression; irritability; anxiety; thoughts of killing or hurting yourself; hallucinating (seeing things or hearing voices that do not exist); frenzied or abnormally excited mood; loss of contact with reality; aggressive behavior; difficulty breathing; fever, chills, cough, sore throat, or other signs of infection; coughing up yellow or pink mucus; burning or pain when urinating, or urinating more often; unusual bleeding or bruising; dark-colored urine; light colored bowel movements; extreme tiredness; yellowing of the skin or eyes; severe muscle or joint pain; or worsening of an autoimmune disease.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to peginterferon alfa-2a.

Your doctor and pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with peginterferon alfa-2a and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Talk to your doctor about the risks of using peginterferon alfa-2a.

Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is also used to treat chronic hepatitis B infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is in a class of medications called interferons. Peginterferon is a combination of interferon and polyethylene glycol, which helps the interferon stay active in your body for a longer period of time. Peginterferon works by decreasing the amount of hepatitis C virus (HCV) or hepatitis B virus (HBV) in the body. Peginterferon alfa-2a may not cure hepatitis C or hepatitis B or prevent you from developing complications of hepatitis C or hepatitis B such as cirrhosis (scarring) of the liver, liver failure, or liver cancer. Peginterferon alfa-2a may not prevent the spread of hepatitis C or hepatitis B to other people.

Peginterferon alfa-2a comes as a solution (liquid) in a vial, a prefilled syringe, and a disposable autoinjector to inject subcutaneously (into the fatty layer just under the skin). It is usually injected once a week, on the same day of the week, and at around the same time of day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use peginterferon alfa-2a exactly as directed. Do not use more or less of this medication or use it more often than prescribed by your doctor.

Your doctor will probably start you on an average dose of peginterferon alfa-2a. Your doctor may decrease your dose if you experience serious side effects of the medication. Be sure to tell your doctor how you are feeling during your treatment and ask your doctor or pharmacist if you have questions about the amount of medication you should take.

Continue to use peginterferon alfa-2a even if you feel well. Do not stop using peginterferon alfa-2a without talking to your doctor.

Only use the brand and type of interferon that your doctor prescribed. Do not use another brand of interferon or switch between peginterferon alfa-2a in vials, prefilled syringes, and disposable autoinjectors without talking to your doctor. If you switch to a different brand or type of interferon, your dose may need to be changed.

You can inject peginterferon alfa-2a yourself or have a friend or relative give you the injections. Before you use peginterferon alfa-2a for the first time, you and the person who will be giving the injections should read the manufacturer's information for the patient that comes with it. Ask your doctor or pharmacist to show you or the person who will be injecting the medication how to inject it. If another person will be injecting the medication for you, be sure that he or she knows how to avoid accidental needlesticks to prevent the spread of hepatitis.

You can inject peginterferon alfa-2a anywhere on your stomach or thighs, except your navel (belly button) and waistline. Use a different spot for each injection. Do not use the same injection spot two times in a row. Do not inject peginterferon alfa-2a into an area where the skin is sore, red, bruised, scarred, infected, or abnormal in any way.

If you do not receive the full prescribed dose because of a problem (such as leakage around the injection site), call your doctor.

Never reuse syringes, needles, or vials of peginterferon alfa-2a. Dispose of used needles and syringes in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.

Before you use peginterferon alfa-2a, look at the solution in the vial, prefilled syringe, or autoinjector closely. Do not shake vials, syringes, or autoinjectors containing peginterferon alfa-2a. The medication should be clear and free of floating particles. Check the vial or syringe to make sure there are no leaks and check the expiration date. Do not use the solution if it is expired, discolored, cloudy, contains particles, or is in a leaky vial or syringe. Use a new solution, and show the damaged or expired one to your doctor or pharmacist.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before using peginterferon alfa-2a,

  • tell your doctor and pharmacist if you are allergic to peginterferon alfa-2a, other alpha interferons, any other medications, benzyl alcohol, or polyethylene glycol (PEG). Ask your doctor if you are not sure if a medication you are allergic to is an alpha interferon.

  • tell your doctor if you have ever received interferon alfa injection for treating hepatitis C infection.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain medications for HIV or AIDS such as abacavir (Ziagen, in Epzicom, in Trizivir), didanosine (ddI or Videx), emtricitabine (Emtriva, in Truvada), lamivudine (Epivir, in Combivir, in Epzicom, in Trizivir), stavudine (Zerit), tenofovir (Viread, in Truvada), zalcitabine (HIVID), and zidovudine (Retrovir, in Combivir, in Trizivir); methadone (Dolophine, Methadose); mexiletine (Mexitil); naproxen (Aleve, Anaprox, Naprosyn, others); riluzole (Rilutek); tacrine (Cognex); telbivudine (Tyzeka); and theophylline (TheoDur, others). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with peginterferon alfa-2a, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • tell your doctor or pharmacist if you have ever had an organ transplant (surgery to replace an organ in the body). Also tell your doctor if you have or have ever had any of the conditions mentioned in the IMPORTANT WARNING section or any of the following: anemia (red blood cells do not bring enough oxygen to other parts of the body), or problems with your eyes or pancreas.

  • tell your doctor if you are pregnant, plan to become pregnant or are breastfeeding. Peginterferon alfa-2a may harm the fetus or cause you to miscarry (lose your baby). Talk to your doctor about using birth control while you are taking this medication. You should not breastfeed while you are taking this medication.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking peginterferon alfa-2a.

  • you should know that peginterferon alfa-2a may make you dizzy, confused, or drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • do not drink alcohol while you are taking peginterferon alfa-2a. Alcohol can make your liver disease worse.

  • you should know that you may experience flu-like symptoms such as headache, fever, chills, tiredness, muscle aches, and joint pain during your treatment with peginterferon alfa-2a. If these symptoms are bothersome, ask your doctor if you should take an over-the-counter pain and fever reducer before you inject each dose of peginterferon alfa-2a. You may want to inject peginterferon alfa-2a at bedtime so that you can sleep through the symptoms.

Drink plenty of fluids while you are taking this medication.

If you remember the missed dose no longer than 2 days after you were scheduled to inject it, inject the missed dose as soon as you remember it. Then inject your next dose on your regularly scheduled day the following week. If more than 2 days have passed since the day you were scheduled to inject the medication, ask your doctor or pharmacist what you should do. Do not use a double dose or use more than one dose in 1 week to make up for a missed dose.

  • Peginterferon alfa-2a may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • bruising, pain, redness, swelling, or irritation in the place you injected peginterferon alfa-2a

    • upset stomach

    • vomiting

    • heartburn

    • dry mouth

    • loss of appetite

    • weight loss

    • diarrhea

    • dry or itchy skin

    • hair loss

    • difficulty falling asleep or staying asleep

    • tiredness

    • weakness

    • difficulty concentrating or remembering

    • sweating

    • dizziness

  • Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them, or those listed in the IMPORTANT WARNING section or the SPECIAL PRECAUTIONS section, call your doctor immediately:

    • blurred vision ,vision changes, or loss of vision

    • lower back pain

    • rash

    • hives

    • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs

    • difficulty swallowing

    • hoarseness

  • Peginterferon alfa-2a may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it in the refrigerator, but do not freeze it. Do not leave peginterferon alfa-2a outside of the refrigerator for more than 24 hours (1 day). Keep peginterferon alfa-2a away from light.

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

If the victim has not collapsed, call the doctor who prescribed this medication. The doctor may want to order lab tests.

Symptoms of overdose may include the following:

  • tiredness

  • unusual bleeding or bruising

  • fever, sore throat, chills, cough, or other signs of infection

Do not let anyone else use your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Leflunomide Leflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Leflunomide.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a.
Anagrelide Anagrelide The metabolism of Anagrelide can be decreased when combined with Peginterferon alfa-2a.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Peginterferon alfa-2a.
Clopidogrel Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Peginterferon alfa-2a.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Peginterferon alfa-2a.
Mycophenolate Mycophenolate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mycophenolic acid.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
Prednisone Prednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisone.
Ranitidine Ranitidine The metabolism of Ranitidine can be decreased when combined with Peginterferon alfa-2a.
Tacrolimus Tacrolimus Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2a.
Tizanidine Tizanidine The metabolism of Tizanidine can be decreased when combined with Peginterferon alfa-2a.
Triamcinolone Triamcinolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Triamcinolone.
Zolmitriptan Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2a.
Interferon Beta-1b Injection Interferon Beta-1b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon gamma-1b.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The metabolism of Metoclopramide can be decreased when combined with Peginterferon alfa-2a.
Zidovudine Injection Zidovudine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.
Cyclosporine Cyclosporine Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.
Enoxaparin Injection Enoxaparin Injection The risk or severity of bleeding can be increased when Enoxaparin is combined with Peginterferon alfa-2a.
Olanzapine Olanzapine The metabolism of Olanzapine can be decreased when combined with Peginterferon alfa-2a.
Alosetron Alosetron The metabolism of Alosetron can be decreased when combined with Peginterferon alfa-2a.
Hydroxychloroquine Hydroxychloroquine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxychloroquine.
Temozolomide Temozolomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temozolomide.
Anakinra Anakinra The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Anakinra.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Linezolid.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Peginterferon alfa-2a.
Etanercept Injection Etanercept Injection The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a.
Sirolimus Sirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sirolimus.
Epirubicin Epirubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Epirubicin.
Adalimumab Injection Adalimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Adalimumab.
Glatiramer Injection Glatiramer Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Glatiramer.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
Frovatriptan Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Peginterferon alfa-2a.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Peginterferon alfa-2a.
Infliximab Injection Infliximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab.
Duloxetine Duloxetine The metabolism of Duloxetine can be decreased when combined with Peginterferon alfa-2a.
Cinacalcet Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Peginterferon alfa-2a.
Natalizumab Injection Natalizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Peginterferon alfa-2a.
Palifermin Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2a.
Entecavir Entecavir The metabolism of Entecavir can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon alfa-2b.
Ramelteon Ramelteon The metabolism of Ramelteon can be decreased when combined with Peginterferon alfa-2a.
Abatacept Injection Abatacept Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Abatacept.
Rasagiline Rasagiline The metabolism of Rasagiline can be decreased when combined with Peginterferon alfa-2a.
Imatinib Imatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Imatinib.
Bevacizumab Injection Bevacizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab.
Bortezomib Bortezomib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clofarabine.
Hepatitis B Vaccine Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2a.
Influenza Vaccine, Inactivated or Recombinant Influenza Vaccine, Inactivated or Recombinant The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
Influenza Vaccine, Live Intranasal Influenza Vaccine, Live Intranasal The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Peginterferon alfa-2a.
Live Shingles (Zoster) Vaccine (ZVL) Live Shingles (Zoster) Vaccine (ZVL) The risk or severity of infection can be increased when Peginterferon alfa-2a is combined with Varicella Zoster Vaccine (Live/attenuated).
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin.
Primaquine Primaquine The metabolism of Primaquine can be decreased when combined with Peginterferon alfa-2a.
Rituximab Injection Rituximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab.
Pemetrexed Injection Pemetrexed Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pemetrexed.
Telbivudine Telbivudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.
Vorinostat Vorinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sunitinib.
Pegaptanib Injection Pegaptanib Injection The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim Injection Pegfilgrastim Injection The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.
Dasatinib Dasatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dasatinib.
Mexiletine Mexiletine The metabolism of Mexiletine can be decreased when combined with Peginterferon alfa-2a.
Azacitidine Injection Azacitidine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azacitidine.
Temsirolimus Temsirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temsirolimus.
Nelarabine Injection Nelarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nelarabine.
Lenalidomide Lenalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lenalidomide.
Nilotinib Nilotinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nilotinib.
Bexarotene Bexarotene The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene.
Budesonide Budesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chloramphenicol.
Decitabine Injection Decitabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Decitabine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitoxantrone.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tretinoin.
Bendamustine Injection Bendamustine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bendamustine.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Peginterferon alfa-2a.
Certolizumab Injection Certolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Irinotecan.
Estramustine Estramustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Estramustine.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Peginterferon alfa-2a.
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.
Dexrazoxane Injection Dexrazoxane Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Peginterferon alfa-2a.
Ibritumomab Injection Ibritumomab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.
Betaxolol Betaxolol The metabolism of Betaxolol can be decreased when combined with Peginterferon alfa-2a.
Prasugrel Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Peginterferon alfa-2a.
Everolimus Everolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Everolimus.
Pralatrexate Injection Pralatrexate Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pralatrexate.
Topotecan Topotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Topotecan.
Golimumab Injection Golimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Golimumab.
Pazopanib Pazopanib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pazopanib.
Asenapine Asenapine The metabolism of Asenapine can be decreased when combined with Peginterferon alfa-2a.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Peginterferon alfa-2a.
Denosumab Injection Denosumab Injection The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2a.
Dabigatran Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2a.
Tocilizumab Injection Tocilizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tocilizumab.
Fingolimod Fingolimod Peginterferon alfa-2a may increase the immunosuppressive activities of Fingolimod.
Eribulin Injection Eribulin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eribulin.
Cabazitaxel Injection Cabazitaxel Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cabazitaxel.
Pegloticase Injection Pegloticase Injection The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2a.
Acetaminophen Injection Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Peginterferon alfa-2a.
Denileukin Diftitox Injection Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.
Sipuleucel-T Injection Sipuleucel-T Injection The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Peginterferon alfa-2a.
Belimumab Injection Belimumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belimumab.
Busulfan Injection Busulfan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Busulfan.
Roflumilast Roflumilast Roflumilast may increase the immunosuppressive activities of Peginterferon alfa-2a.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cyclophosphamide.
Rivaroxaban Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Peginterferon alfa-2a.
Ticagrelor Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2a.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brentuximab vedotin.
Ruxolitinib Ruxolitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib.
Belatacept Injection Belatacept Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belatacept.
Basiliximab Injection Basiliximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Peginterferon alfa-2a.
Melphalan Injection Melphalan Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Melphalan.
Eculizumab Injection Eculizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eculizumab.
Fondaparinux Injection Fondaparinux Injection The risk or severity of bleeding can be increased when Fondaparinux is combined with Peginterferon alfa-2a.
Pertuzumab Injection Pertuzumab Injection The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Pertuzumab.
Carfilzomib Injection Carfilzomib Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Peginterferon alfa-2a.
Bosutinib Bosutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Corticotropin.
Teriflunomide Teriflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teriflunomide.
Icosapent Ethyl Icosapent Ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2a.
Tofacitinib Tofacitinib Peginterferon alfa-2a may increase the immunosuppressive activities of Tofacitinib.
Dimethyl Fumarate Dimethyl Fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dimethyl fumarate.
Ponatinib Ponatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ponatinib.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trastuzumab emtansine.
Apixaban Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Peginterferon alfa-2a.
Perampanel Perampanel The metabolism of Perampanel can be decreased when combined with Peginterferon alfa-2a.
Ibrutinib Ibrutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibrutinib.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Obinutuzumab.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Peginterferon alfa-2a.
Apremilast Apremilast The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Apremilast.
Siltuximab Injection Siltuximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siltuximab.
Vedolizumab Injection Vedolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vedolizumab.
Belinostat Injection Belinostat Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belinostat.
Idelalisib Idelalisib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib.
Vorapaxar Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Peginterferon alfa-2a.
Edoxaban Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Peginterferon alfa-2a.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon beta-1a.
Olaparib Olaparib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Olaparib.
Blinatumomab Injection Blinatumomab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Blinatumomab.
Tasimelteon Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Peginterferon alfa-2a.
Pirfenidone Pirfenidone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pirfenidone.
Secukinumab Injection Secukinumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Secukinumab.
Palbociclib Palbociclib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Palbociclib.
Panobinostat Panobinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Panobinostat.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a.
Prednisolone Prednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisolone.
Mepolizumab Injection Mepolizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mepolizumab.
Trabectedin Injection Trabectedin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trabectedin.
Dexamethasone Injection Dexamethasone Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone.
Defibrotide Injection Defibrotide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2a.
Ixekizumab Injection Ixekizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixekizumab.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Peginterferon alfa-2a.
Brodalumab Injection Brodalumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brodalumab.
Doxepin (Insomnia) Doxepin (Insomnia) The metabolism of Doxepin can be decreased when combined with Peginterferon alfa-2a.
Deflazacort Deflazacort The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Deflazacort.
Ocrelizumab Injection Ocrelizumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ocrelizumab.
Sarilumab Injection Sarilumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sarilumab.
Guselkumab Injection Guselkumab Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Guselkumab.
Enasidenib Enasidenib The metabolism of Enasidenib can be decreased when combined with Peginterferon alfa-2a.
Betrixaban Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Peginterferon alfa-2a.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.
Penicillamine Penicillamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Penicillamine.
Baricitinib Baricitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Baricitinib.
Lofexidine Lofexidine The metabolism of Lofexidine can be decreased when combined with Peginterferon alfa-2a.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Peginterferon alfa-2a.
Pegvaliase-pqpz Injection Pegvaliase-pqpz Injection The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginterferon alfa-2a.
Stiripentol Stiripentol The metabolism of Stiripentol can be decreased when combined with Peginterferon alfa-2a.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Peginterferon alfa-2a is combined with Methoxy polyethylene glycol-epoetin beta.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paclitaxel.
Ravulizumab-cwvz Injection Ravulizumab-cwvz Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ravulizumab.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Emapalumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Peginterferon alfa-2a.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2a.
Risankizumab-rzaa Injection Risankizumab-rzaa Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Risankizumab.
Cladribine Cladribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cladribine.
Triclabendazole Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Peginterferon alfa-2a.
Pexidartinib Pexidartinib Peginterferon alfa-2a may increase the hepatotoxic activities of Pexidartinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Peginterferon alfa-2a.
Ozanimod Ozanimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ozanimod.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Peginterferon alfa-2a.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.
Indomethacin Indomethacin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Indomethacin.
Naproxen Naproxen The metabolism of Naproxen can be decreased when combined with Peginterferon alfa-2a.
Hydroxyurea Hydroxyurea The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxyurea.
Floxuridine Floxuridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Floxuridine.
Methotrexate Injection Methotrexate Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methotrexate.
Chlorpromazine Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Peginterferon alfa-2a.
Carmustine Carmustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine.
Thioguanine Thioguanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tioguanine.
Trifluoperazine Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Peginterferon alfa-2a.
Bleomycin Bleomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleomycin.
Methadone Methadone The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.
Maprotiline Maprotiline The metabolism of Maprotiline can be decreased when combined with Peginterferon alfa-2a.
Perphenazine Perphenazine The metabolism of Perphenazine can be decreased when combined with Peginterferon alfa-2a.
Azathioprine Azathioprine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azathioprine.
Sulfasalazine Sulfasalazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sulfasalazine.
Lomustine Lomustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lomustine.
Doxorubicin Doxorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Doxorubicin.
Cytarabine Cytarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.
Mechlorethamine Mechlorethamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mechlorethamine.
Dactinomycin Dactinomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dactinomycin.
Carbamazepine Carbamazepine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carbamazepine.
Clonidine Clonidine The metabolism of Clonidine can be decreased when combined with Peginterferon alfa-2a.
Warfarin Warfarin The metabolism of Warfarin can be decreased when combined with Peginterferon alfa-2a.
Daunorubicin Daunorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.
Digoxin Digoxin Digoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
Quinine Quinine The metabolism of Quinine can be decreased when combined with Peginterferon alfa-2a.
Triamterene Triamterene The metabolism of Triamterene can be decreased when combined with Peginterferon alfa-2a.
Sulfinpyrazone Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2a.
Chlorothiazide Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Peginterferon alfa-2a.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Peginterferon alfa-2a.
Imipramine Imipramine The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a.
Disopyramide Disopyramide The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a.
Tamoxifen Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Peginterferon alfa-2a.
Mitomycin Mitomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitomycin.
Methimazole Methimazole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methimazole.
Propylthiouracil Propylthiouracil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil.
Cyclobenzaprine Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Peginterferon alfa-2a.
Methyclothiazide Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2a.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Peginterferon alfa-2a.
Chlorzoxazone Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Peginterferon alfa-2a.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The metabolism of Propranolol can be decreased when combined with Peginterferon alfa-2a.
Mercaptopurine Mercaptopurine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mercaptopurine.
Allopurinol Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Peginterferon alfa-2a.
Fluorouracil Injection Fluorouracil Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluorouracil.
Colchicine Colchicine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Colchicine.
Dacarbazine Dacarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dacarbazine.
Bacillus Calmette-Guerin (BCG) Vaccine Bacillus Calmette-Guerin (BCG) Vaccine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Peginterferon alfa-2a.
Thiotepa Injection Thiotepa Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thiotepa.
Vincristine Injection Vincristine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine.
Dipyridamole Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2a.
Vinblastine Vinblastine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinblastine.
Thiothixene Thiothixene The metabolism of Thiothixene can be decreased when combined with Peginterferon alfa-2a.
Aspirin Aspirin The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2a.
Chlorambucil Chlorambucil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chlorambucil.
Nifedipine Nifedipine The metabolism of Nifedipine can be decreased when combined with Peginterferon alfa-2a.
Verapamil Verapamil The metabolism of Verapamil can be decreased when combined with Peginterferon alfa-2a.
Cisplatin Injection Cisplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cisplatin.
Streptozocin Streptozocin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Streptozocin.
Etoposide Etoposide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Etoposide.
Pentoxifylline Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Peginterferon alfa-2a.
Guanabenz Guanabenz The metabolism of Guanabenz can be decreased when combined with Peginterferon alfa-2a.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Peginterferon alfa-2a.
Diclofenac Diclofenac The metabolism of Diclofenac can be decreased when combined with Peginterferon alfa-2a.
Fluoxetine Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Peginterferon alfa-2a.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b.
Clozapine Clozapine The risk or severity of neutropenia can be increased when Peginterferon alfa-2a is combined with Clozapine.
Idarubicin Idarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idarubicin.
Fludarabine Injection Fludarabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fludarabine.
Pentostatin Injection Pentostatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pentostatin.
Nabumetone Nabumetone The metabolism of Nabumetone can be decreased when combined with Peginterferon alfa-2a.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Peginterferon alfa-2a.
Teniposide Injection Teniposide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teniposide.
Zolpidem Zolpidem The metabolism of Zolpidem can be decreased when combined with Peginterferon alfa-2a.
Fluvoxamine Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Peginterferon alfa-2a.
Vinorelbine Injection Vinorelbine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin.
Ifosfamide Injection Ifosfamide Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ifosfamide.
Pegaspargase Injection Pegaspargase Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase.
Ticlopidine Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Peginterferon alfa-2a.
Dalteparin Injection Dalteparin Injection The risk or severity of bleeding can be increased when Dalteparin is combined with Peginterferon alfa-2a.
Riluzole Riluzole The metabolism of Riluzole can be decreased when combined with Peginterferon alfa-2a.
Anastrozole Anastrozole The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Anastrozole.
Gemcitabine Injection Gemcitabine Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemcitabine.
Docetaxel Injection Docetaxel Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Docetaxel.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Peginterferon alfa-2a.
Mirtazapine Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Peginterferon alfa-2a.
Zileuton Zileuton The metabolism of Zileuton can be decreased when combined with Peginterferon alfa-2a.
Carvedilol Carvedilol The metabolism of Carvedilol can be decreased when combined with Peginterferon alfa-2a.
Flutamide Flutamide The metabolism of Flutamide can be decreased when combined with Peginterferon alfa-2a.
Selegiline Selegiline The metabolism of Selegiline can be decreased when combined with Peginterferon alfa-2a.
Propafenone Propafenone The metabolism of Propafenone can be decreased when combined with Peginterferon alfa-2a.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ropinirole.
Paroxetine Paroxetine The metabolism of Paroxetine can be decreased when combined with Peginterferon alfa-2a.
Capecitabine Capecitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Capecitabine.
Efavirenz Efavirenz The metabolism of Efavirenz can be decreased when combined with Peginterferon alfa-2a.
Trastuzumab Injection Trastuzumab Injection Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a.
Thalidomide Thalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thalidomide.
Terbinafine Terbinafine The metabolism of Terbinafine can be decreased when combined with Peginterferon alfa-2a.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists